118 related articles for article (PubMed ID: 38864578)
1. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV: a longitudinal cohort study.
Hwang YJ; Lesko CR; Brown TT; Alexander GC; Zalla LC; Keruly JC; Snow LN; Pytell JD; Falade-Nwulia O; Jones JL; Moore RD; Fojo AT
AIDS; 2024 Jun; ():. PubMed ID: 38864578
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
4. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
[TBL] [Abstract][Full Text] [Related]
5. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
6. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
7. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
8. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
9. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
10. Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors.
Chen YW; Hardy H; Pericone CD; Chow W
J Health Econ Outcomes Res; 2020; 7(2):102-110. PubMed ID: 32766375
[TBL] [Abstract][Full Text] [Related]
11. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
12. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.
Verburgh ML; Wit FWNM; Boyd A; Verboeket SO; Reiss P; van der Valk M
Open Forum Infect Dis; 2022 Jul; 9(7):ofac291. PubMed ID: 35873291
[TBL] [Abstract][Full Text] [Related]
13. Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors.
Chen YW; Anderson D; Pericone CD; Donga P
J Health Econ Outcomes Res; 2022; 9(1):1-10. PubMed ID: 35083364
[No Abstract] [Full Text] [Related]
14. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
18. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
19. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
